Strides Pharma Science Limited has informed the Exchange about Schedule of meet and Presentation
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Strides Pharma Science has informed the exchanges that its management will attend an investor conference organized by Emkay Global Financial Services on August 12, 2025, in Mumbai. The Q1 FY26 earnings deck (originally shared on July 29, 2025) will serve as the discussion document. The attached deck shows a strong quarter: revenue grew 6.2% YoY to ₹11,197m, gross margin expanded 300bps to 60.3%, EBITDA rose 14.8% to ₹2,181m (margin up 150bps to 19.5%), and operational PAT surged 80.6% YoY to ₹1,140m, with operational EPS of ₹12.4. The US business grew 7% YoY to $71m, other regulated markets rose 9.2% to $42m, and growth markets jumped 32.2% to $16.4m, while access markets declined sharply due to weak donor funding. Net debt fell ₹264m to ₹14,958m, credit rating was upgraded to 'CARE A Positive', and the company reiterated its US revenue target of ~$400m by FY27-28.
The filing is procedural, but the attached deck signals robust operational momentum with broad-based margin expansion, record quarterly PAT, and improving balance sheet strength (debt reduction plus credit rating upgrade), which should be viewed positively by investors. Management's investor outreach may sustain near-term stock interest.